Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 203799 in Lymphoma Patients Undergoing Myeloablative Chemotherapy
NCT03417765Phase 2Withdrawn
- Sponsor
- GLyPharma Therapeutic
- Start
- Sep 2018
- Primary completion
- Mar 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of apraglutide in gastrointestinal mucositis, sponsored by GLyPharma Therapeutic. Planned start Sep 2018; status: withdrawn.
02
Drugs
apraglutide
03
Conditions
gastrointestinal mucositis
Beyond the preview
Go deeper on NCT03417765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417765.